Your browser doesn't support javascript.
loading
Development of selective cytotoxic viral vectors for concentration of undifferentiated cells in cardiomyocytes derived from human induced pluripotent stem cells.
Kono, Ken; Sawada, Rumi; Kuroda, Takuya; Yasuda, Satoshi; Matsuyama, Satoko; Matsuyama, Akifumi; Mizuguchi, Hiroyuki; Sato, Yoji.
Afiliación
  • Kono K; Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan.
  • Sawada R; Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan.
  • Kuroda T; Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan.
  • Yasuda S; Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan.
  • Matsuyama S; Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kanagawa, Japan.
  • Matsuyama A; Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health and Nutrition, Hyogo, Japan.
  • Mizuguchi H; Department of Regenerative Medicine, School of Medicine, Fujita Health University, Aichi, Japan.
  • Sato Y; Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Sci Rep ; 9(1): 3630, 2019 03 06.
Article en En | MEDLINE | ID: mdl-30842516
ABSTRACT
Cell-processed therapeutic products (CTPs) derived from human pluripotent stem cells (hPSCs) have innovative applications in regenerative medicine. However, undifferentiated hPSCs possess tumorigenic potential; thus, sensitive methods for the detection of residual undifferentiated hPSCs are essential for the clinical use of hPSC-derived CTPs. The detection limit of the methods currently available is 1/105 (0.001%, undifferentiated hPSCs/differentiated cells) or more, which could be insufficient for the detection of residual hPSCs when CTPs contain more than 1 × 105 cells. In this study, we developed a novel approach to overcome this challenge, using adenovirus and adeno-associated virus (AdV and AAV)-based selective cytotoxic vectors. We constructed AdV and AAV vectors that possess a suicide gene, iCaspase 9 (iCasp9), regulated by the CMV promoter, which is dormant in hPSCs, for the selective expression of iCasp9 in differentiated cells. As expected, AdV/CMV-iCasp9 and AAV/CMV-iCasp9 exhibited cytotoxicity in cardiomyocytes but not in human induced pluripotent stem cells (hiPSCs). The vectors also induced apoptosis in hiPSC-derived cardiomyocytes, and the surviving cells exhibited higher levels of hPSC marker expression. These results indicate that the AdV- and AAV-based cytotoxic vectors concentrate cells expressing the undifferentiated cell markers in hiPSC-derived products and are promising biological tools for verifying the quality of CTPs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diferenciación Celular / Adenoviridae / Dependovirus / Miocitos Cardíacos / Medicina Regenerativa / Células Madre Pluripotentes Inducidas / Vectores Genéticos Límite: Humans Idioma: En Revista: Sci Rep Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diferenciación Celular / Adenoviridae / Dependovirus / Miocitos Cardíacos / Medicina Regenerativa / Células Madre Pluripotentes Inducidas / Vectores Genéticos Límite: Humans Idioma: En Revista: Sci Rep Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM